Profound Medical Corp. provided revenue guidance for the fourth quarter and full year 2017. For the quarter, the company anticipates total revenues for the fourth quarter of 2017 to be approximately $1.9 million, compared to nil in the fourth quarter of 2016, and reflecting an approximate 30% increase sequentially over the previous quarter.

For the full year 2017, the company anticipates total revenues to be approximately $4.9 million.

The company also reported that, as of December 31, 2017, the company-sponsored TACT pivotal clinical study, designed to further evaluate the safety and efficacy of TULSA-PRO® to ablate prostate tissue in patients with localized, organ-confined prostate cancer, had reached 87% (96 out of 110) patient enrollment. With an additional 14 patients still to be treated, Profound expects to complete study enrollment at some point during the month of February 2018.